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Background. NOS/∙NO inhibitors are potential therapeutics for sepsis, yet they increase clinical mortality. However, there has
been no in vivo investigation of the (in vitro) ∙NO scavenger, cobalamin’s (Cbl) endogenous effects on NOS/∙NO/inflammatory
mediators during the immune response to sepsis. Methods. We used quantitative polymerase chain reaction (qPCR), ELISA,
Western blot, and NOS Griess assays, in a C57BL/6 mouse, acute endotoxaemia model. Results. During the immune response,
pro-inflammatory phase, parenteral hydroxocobalamin (HOCbl) treatment partially inhibits hepatic, but not lung, iNOS mRNA
and promotes lung eNOS mRNA, but attenuates the LPS hepatic rise in eNOS mRNA, whilst paradoxically promoting high
iNOS/eNOS protein translation, but relatively moderate ∙NO production. HOCbl/NOS/∙NO regulation is reciprocally associated
with lower 4 h expression of TNF-𝛼, IL-1𝛽, COX-2, and lower circulating TNF-𝛼, but not IL-6. In resolution, 24 h after LPS,
HOCbl completely abrogates a major late mediator of sepsis mortality, high mobility group box 1 (HMGB1) mRNA, inhibits
iNOS mRNA, and attenuates LPS-induced hepatic inhibition of eNOS mRNA, whilst showing increased, but still moderate, NOS
activity, relative to LPS only. experiments (LPS+D-Galactosamine) HOCbl afforded significant, dose-dependent protection inmice
Conclusions. HOCbl produces a complex, time- and organ-dependent, selective regulation of NOS/∙NO during endotoxaemia,
corollary regulation of downstream inflammatory mediators, and increased survival. This merits clinical evaluation.
1. Introduction
Cobalamin, C
63
H
88
O
14
N
14
PCo (Figure 1), participates in
only two known mammalian enzymatic reactions. Yet, these
two Cbl-dependent enzymes, cytosolic methionine synthase
(MS) [EC 2.1.1.13], requiring methylcobalamin (MeCbl),
and mitochondrial methylmalonyl-CoA mutase (MU) [EC
5.4.99.2], requiring adenosylcobalamin (AdoCbl) [1, 2],
are critically involved in key metabolic pathways essential
for gene expression and regulation, via formation of S-
adenosylmethionine (SAM) and methylation, and in protein
synthesis and catabolism, cellular respiration, and energy.
Activation of methionine synthase also ensures key antiox-
idant defense status, as it triggers concurrent activation of
cystathionine 𝛽-synthase (C𝛽S), the pivotal enzyme at the
homocysteine junction in the trans-sulfuration pathway to
glutathione (GSH) [3].
2 Mediators of Inflammation
H2NOC CONH2
CONH2
CONH2
H2NOC
H2NOC
X
NN
N N
Co
N
N
H
H
CH3
CH3
O
O
O
O
HN
OH
HO
P
O O−
H3C
X = -CN
-HO
-GSH
-NAC
-CH3
-AdoCH3
Figure 1: The structure of cobalamin. X = the principal ligands for
the cobalt atom, in the upper, 𝛽 axial position.
Cobalamin is the standard treatment for autoimmune
“pernicious” anaemia, and macrocytic or megaloblastic
anaemia, as well as for subacute combined degeneration
of the spinal cord. However, an increasing body of work
suggests that Cbl may also play a central role in the reg-
ulation of immunity and inflammation (reviewed in [4]).
Cbl confers significant protection in various animal models
of shock, from anaphylaxis to trauma and sepsis [5–7], and
has remarkable organ/tissue protective effects when used
clinically for the treatment of analogous inflammation in CN
poisoning (reviewed in [8]). Amongst Cbl’s known immuno-
logical effects are an augmentation of the CD8+/CD4+ T-
lymphocyte ratio and natural killer cell activity [9, 10],
both significantly reduced in inflammatory pathology, with
negative consequences in septic patients [11].
Interesting homeostatic links between Cbl and pivotal
cytokines are also emerging, indicative of complex but
still incompletely defined regulatory circuits: MeCbl lowers
interleukin-6 (IL-6) expression in peripheral blood mono-
cytes [12], whilst Cbl deficiency raises circulating IL-6 in
humans [13] and Cbl physiological status regulates IL-6 levels
in rat cerebrospinal fluid [14]. Moreover, in both rodents
and humans there appears to be an inverse relation between
Cbl physiological levels and tumour necrosis factor alpha
(TNF-𝛼) serum levels [15]. In vitro, neuronal Cbl deficiency
is also associated with increased expression of two TNF-𝛼-
converting enzyme secretases [16]. A reasonable hypothesis is
that such Cbl/TNF-𝛼/IL-6 regulation may be partly effected
via Cbl indirect regulation of the central immune regulatory
transcription factor, nuclear factor kappa B (NF-𝜅B) [8].
Normal physiological levels of Cbl in spinal fluid appear
to correlate with NF-𝜅B quiescence, at least, in a non-
inflammatory/non-immune challenge model [17]. Recently,
a kinetic study reported thatCob(II)alamin reactswith super-
oxide at rates approaching superoxide dismutase [18]. CNCbl
protects human aortic endothelial cells, and neuronal cells, in
vitro, against superoxide induced injury [19, 20]. Given that
oxidative stress is a major trigger of NF-𝜅B activation, this
potential antioxidant effect of Cbl could theoretically lead to
NF-𝜅B inhibition. It may also be of critical local importance
in vivo, as the phagocytic burst includes release of the Cbl
carrier, haptocorrin (HC/TC 3), in the immediate vicinity
of NADPH oxidase [8, 21] one of the major biochemical
sources of superoxide in immune challenge and inflamma-
tion [22]. HC/TC3, moreover, is upregulated by IL-1𝛽, itself
expressed within fifteen minutes of inflammatory challenge
[23]. Nevertheless, though antioxidant effects of Cbls have
been observed in vitro [24] and may, indeed, be important in
vivo [20], no systematic analysis of the in vivomechanisms of
Cbl conferred protection against inflammation during acute
immune challenge has hitherto been done.
We wondered if a more comprehensive explanation for
Cbl effects on inflammation and immunity, and thence
beneficial outcomes in sepsis and other forms of shock, may
lie in a potential direct/indirect regulation by Cbl of one
or more of the several actions of nitric oxide ( ∙NO) as
a ubiquitous, cell-signal transduction molecule and second
messenger for post-translational modification, whose targets
include soluble guanylate cyclase [25]. ∙NO is the product of
three nitric oxide synthases (NOS): two constitutive, nNOS
(neuronal NOS; NOS I) and eNOS (endothelial NOS; NOS
III), and one inducible, iNOS (NOS II), at much higher levels
of expression, with the potential to produce 1000-fold higher
than normal amounts of ∙NO, during gestation, growth, and
the immune response [26]. Cobalamins are known to have
effects on ∙NO [27–29], but these have hitherto been thought
to be a consequence of Cbl/ ∙NO scavenging effects [7, 30–35]
demonstrable chemically and in vitro [36, 37], but biologically
unproven in vivo and still controversial [38–40].
Nitrosylcobalamin has not been detected, to date, in vivo
or in vitro, amongst naturally occurring intracellular Cbls
[41]. Nevertheless, if the hypothesis that Cbl is involved
in NOS catalysis has any substance [42, 43], then it is
conceivable that, in analogy to previously observed ferric-
heme-NO complex formation at the conclusion of NOS
catalysis [44], NOCbl might be transiently formed, just prior
to release of free ∙NO by the NOS [43]. Such a theoretical
transience and discrete localisation might account for the
failure to detect NOCbl in vivo to date. Ubiquitous and
continuous Cbl scavenging of ∙NO, on the other hand,
may pose biochemical hazards. For ∙NO has important
antioxidant and cell-signalling actions [25] which might be
obstructed by HOCbl’s previously proposed, indiscriminate
∙NO scavenging, or even just by a recently proposed, Cbl
structural-based, direct inhibition of the NOS tout court and
nothing else [45]. There is some evidence that HOCbl can
discriminate between exogenous ∙NOdonors and the natural
endogenous donor, S-nitrosoglutathione, GSNO, actually
prolonging only GSNO-induced, gastric fundus relaxations
[46]. This hints at a more complex Cbl/ ∙NO regulatory
relationship.
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Moreover, there are also diverse indications that positive
Cbl status is allied to beneficial ∙NO activity: in diabetic
rats, high cobalamin levels correlate with high NOS protein
levels, ∙NO activity, and increased erectile function [47]; Cbl
supplementation of vegetarians with low Cbl status signif-
icantly increases eNOS ∙NO release in the brachial artery
[48]; in the digestive tract of endotoxemic rats, the highest
expression of iNOS is in the ileum, precisely where Cbl is
internalized [49], and both Cbl and ∙NO are known to medi-
ate cell protective effects via ERK1/2 and Akt [50–54]. These
protective effects of ∙NO and Cbl include induction and
regulation of heme oxygenase-1 (HO-1) [52, 55–58], which
converts biliverdin to the powerful antioxidant bilirubin, and
carbon monoxide. CO can then in turn decrease ∙NO [59].
(For amore comprehensive list of coincidences ofCbl’s/ ∙NO’s
positive actions, see Table 1 and its related discussion in
[43]).
Thus, in these studies we explored an alternative hypoth-
esis to that of Cbl as just an ∙NO, or, indeed, superoxide,
mop. We posited that the principal mechanism behind
Cbl’s beneficial, pleiotropic effects in inflammation may
involve a biphasic regulation of NOS expression and protein
translation and the ensuing ∙NO synthesis, during the two
distinct pro- and anti-inflammatory phases of the immune
response.
2. Materials and Methods
2.1. Animals. Male C57BL/6 mice, weighing 20 to 25 g,
were purchased from Harlan, UK, and maintained on a
standard chow pellet diet, containing standard amounts of
Cbl (50𝜇g/kg vitamin B12/CNCbl), with tap water supplied
ad libitum. Animals were kept in a 12:00 h light/dark cycle,
and all were housed for 7 days prior to experimentation. All
experiments were performed in accordance with UK Home
Office regulations (Guidance On the Operation of Animals:
Scientific Procedures Act, 1986).
2.2. Cobalamins. The coenzymes, 5󸀠-deoxyadenosylcobala-
min, and methylcobalamin; Vitamin B
12
a, cyanocobalamin,
and hydroxocobalamin (CAS 78091-12-0) were purchased
from Sigma-Aldrich (UK). Glutathionylcobalamin and N-
acetyl-cysteinyl-cobalamin were synthesized and supplied by
Professor Nicola Brasch (Kent State University, Ohio, USA).
All Cbls (and Cbl-treated animal samples) were protected
from light during storage and handling, and were 98% to
99.5% pure.
2.3. Drug Treatment and Experimental Design. 5󸀠-deoxyade-
nosylcobalamin (AdoCbl), methylcobalamin (MeCbl), hy-
droxocobalamin (HOCbl), glutathionylcobalamin (GSCbl),
and N-acetyl-cysteinyl-cobalamin (NAC-Cbl) were all stored
at−20∘C, and fresh solutions of themweremade using sterile,
pyrogen-free, phosphate-buffered saline (PBS; Gibco), prior
to the experiments. For the in vivo experiments, cobalamins
were diluted at 10mL/kg prior to treatments (with PBS used
as vehicle). Cobalamins were administered according to the
protocol summarized in Table 1.
2.4. Effects of Endogenous Cobalamins on NF-𝜅B Promoter
Activity. RAW 246.7 macrophage cells, stably transfected
with NF-𝜅B luciferase reporter construct (Stratagene), were
maintained in Dulbecco’s modified Eagle’s medium, supple-
mentedwith 10% (v/v) fetal bovine serum, 2mM l-glutamine,
1 𝜇g/mL Geneticin, and 50𝜇g/mL G418. Cells (2 × 104 cells)
were seeded in 96-well plates and then preincubated for
1 h with increasing concentrations (1–10–100𝜇M) of the five
principally occurring, intracellular Cbls. Thereafter, at time
0 h, cells were stimulated with E. coli LPS (0111 : B4; 1𝜇g) for
4 h and then processed for measurement of luciferase activity
in a luminometer (Luminometer TD-20/20; Turner Designs
Instruments).
2.5. Non-Lethal and Lethal Endotoxaemia. Endotoxaemia
was induced by the intraperitoneal injection of LPS
(0.1mg/kg), alone (non-lethal) or, in the lethal endotoxaemia
protocol, in combination with 1 g/kg D-Galactosamine
(Table 1). Sample collection in non-lethal endotoxaemia
was carried out at both 4 and 24 h after LPS challenge.
Animal survival, in all lethal endotoxaemia experiments, was
monitored for a total of 5 days, and all data were analysed
using Chi-squared or Kaplan-Meier tests.
Times shown are in relation to time 0 h, when either
LPS alone or LPS+D-Gal was administered by intraperitoneal
injection. Individual cobalamins were injected into the peri-
toneum at the doses and times reported in Table 1.
2.6. Sample Preparation for Real-Time Reverse Transcriptase-
PCR. Blood (500𝜇L) was centrifuged (for 5min, at 2500
rpm), and the plasma then collected for ELISA analysis.
500𝜇L of TRIZOL reagent (Invitrogen) was added to the
remaining fraction. RNA purification was performed as
recommended by the manufacturer. Following extraction,
RNA (20𝜇L) was treated with 2U (1𝜇L) of TURBO DNase
1 (Ambion, Austin, TX), as described by the manufacturer, to
remove any contaminating genomic DNA. An aliquot of the
DNA-free RNA (7.6 𝜇L) was then transferred to a newRNase-
free tube and reverse-transcribed into complementary DNA
(cDNA), using Superscript III Reverse Transcriptase (Invit-
rogen), as described by manufacturer.The following reagents
were used: Oligo dT primers (Invitrogen); 1𝜇L, 10mMdNTP
(Bioline); 4𝜇L of 5X first-strand buffer; 1 𝜇L, 0.1 M DTT;
1 𝜇L (40U) RNaseOUT; and 1 𝜇L (200U) of Superscript III
Reverse Transcriptase (Invitrogen). After synthesis, cDNA
was quantified using a Nanodrop ND-1000 and diluted
(80 ng/𝜇L) in molecular biology grade water and then loaded
into 384-well plates for real-time PCR.
2.7. Real-Time Reverse Transcriptase PCR. Real-time PCR
assays were performed on the various samples in order to
evaluate the expression of the following genes: GAPDH,
RPL32, IL-1𝛽, COX-2, iNOS, eNOS, TNF-𝛼, and HMGB1
(Table 2). For each gene analyzed, reactions were performed
using 1𝜇L of the Qiagen QuantiTect Primer Assay, added to
5 𝜇L Power SyBR Green PCR Master Mix (Applied Biosys-
tems, Warrington, UK) and then diluted with 2𝜇L molecular
grade water. A final volume of 8 𝜇L was dispensed into each
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Table 1: Protocol for cobalamin treatment of LPS-induced endotoxaemia.
Experimental protocols Inflammatory stimulus Treatment
Cbl dose Time of Cbl treatment
4 h non-lethal LPS (0.1mg/kg) 0.2mg/kg −1 h, +1 h, +2 h
24 h non-lethal LPS (0.1mg/kg) 0.2mg/kg −1, +1, +2, +6, +22 h
Lethal series I LPS (0.1mg/kg) 0.2mg/kg −1, +1, +2, +6, +22 h
+ D-Gal (1 g/kg) 40mg/kg +2, +22 h
Lethal series II LPS (0.1mg/kg) 40mg/kg HOCbl +2, +4 h
+ D-Gal (1 g/kg) 80mg/kg HOCbl +2 h
Table 2
Assay code Gene and accession number ofdetected transcripts
QT00100275 NOS2; NM 010927
QT00152754 NOS3; NM 008713
QT00247786 HMGB1; NM 010439
QT00104006 TNF-𝛼; NM 013693
QT01048355 IL-1𝛽; NM 008361
QT01658692 GADPH; NM 008084
QT01752387 RPL32; NM 172086
well and 2 𝜇L of diluted cDNA (160 ng/reaction) was added.
Each sample was tested in triplicate for each gene, and PCR
reactions were performed using ABI Prism 7900 real-time
PCR equipment. The thermal profile consisted of 95∘C for
15min, then 40 cycles of 94∘C for 15 s, 55∘C for 30 s, and 72∘C
for 30 s. This was plotted as a melting curve. The comparison
between samples was performed using GAPDH and RPL32
as internal standards. REST MCS software was utilized for
the calculation of the relative difference between the test
groups.
2.8. iNOS and eNOSWestern Blotting. Liver tissues were har-
vested from (𝑛 = 5) animals, after LPS endotoxaemia, with
or without HOCbl treatment and then homogenized in lysis
buffer, which contained a cocktail of protease inhibitors. Pro-
tein concentrations prior to loading were determined using
the Bradford assay (Sigma): samples were mixed with 6x
Laemmli sample buffer, and equal protein amounts (100𝜇g)
then underwent electrophoresis on a 10% polyacrylamide
gel in running buffer (0.3% Tris base, 1.44% glycine, and
0.1% SDS in distilled water). This was followed by transfer
of the proteins onto PVDF membranes in transfer buffer
(using 0.3% Tris base, 1.44% glycine, and 20% methanol,
in distilled water). Membranes were blocked for 1 h with
5% nonfat milk solution in TBS containing 0.1% Tween 20.
iNOS expression was assessed using a specific monoclonal
antibody (1 : 1000; SantaCruz,USA).The signal was amplified
with HRP-linked anti-mouse secondary antibody (1 : 2000)
and visualized by ECL (Western blotting detection reagent;
Amersham Biosciences, USA). Densitometric analysis was
performed using NIH ImageJ software and normalised to
tubulin loading controls in the same sample.
2.9. NOSActivity: Nitrate/Nitrite Production Assays. Animals
(𝑛 = 5) were challenged with LPS and treated with Cbls as
described above. At 4 h and 24 h after LPS challenge, lung
and liver tissue samples were harvested, homogenized, and
processed for determination of NOS activity, as measured
by nitrate/nitrite end-products of NO. The ultrasensitive,
NOS assay used (Oxford Biomedical Research, Oxford, MI,
USA: ultrasensitive colorimetric NOS assay: cat no. NB78)
employs an NADPH recycling system—NADP+, glucose-
6-phosphate, glucose-6-phosphate dehydrogenase and the
substrate, L-arginine, but not the cofactor, BH
4
,—to ensure
that NOS operate linearly for up to 6 hours, as NO-derived
nitrate and nitrite accumulate. The assay kit can accurately
measure as little as 1 pmol/milliL (∼1milliM) ∙NO produced
in aqueous solution. In these studies, the assay was run for 5 h
at 37∘C.The enzyme nitrate reductase was used to convert all
nitrate to nitrite, then Griess reagent employed to quantify
nitrite levels, with the generation of a nitrite standard, as
recommended by the supplier. The completed reaction was
read at 540 nm in aMicrotiter plate reader. Data are expressed
as mmol nitrite/𝜇g protein.
2.10. Determination of Tumour Necrosis Factor Alpha (TNF-
𝛼) and Interleukin (IL-6) Levels. After collection, blood was
centrifuged and the plasma separated, under low lighting
conditions, then stored at −80∘C until performance of the
analyses. For determination of circulating TNF-𝛼 and IL-
6 levels, using ELISA assays, samples were diluted 1 : 10 in
the assay diluent, as specified by the manufacturer (R&D,
UK). Absorbance was plotted in a standard curve, and data
expressed as the content of TNF-𝛼 (ng) or IL-6 (pg) per mL
of plasma.
2.11. Reagents. Unless otherwise stated, all reagents were
purchased from Sigma-Aldrich, Poole, UK.
2.12. Statistics. Data are shown as a mean ± S.E. of 5
animals per group for the analyses in non-lethal endotox-
aemia and, initially, 7–9 per group, then 12 per group, for
lethal endotoxaemia survival, series I and II, respectively.
Statistical differences were determined by ANOVA, following
the Student Newman Keuls test. Chi-square and Kaplan-
Meier tests were used for the lethality studies. In all cases, a
𝑃 < 0.05 was taken as significant.
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3. Results
3.1. Cobalamins DoNot Inhibit LPS-InducedNF-𝜅BActivation
In Vitro. Since Cbl has been shown to prevent NF-𝜅B activa-
tion in a non-immune challengemodel [17], and activation of
NF-𝜅B leads to iNOS induction, we first looked at the effects
of the five principally occurring, intracellular Cbls, (CNCbl,
HOCbl, GSCbl, and the two mammalian enzyme cofactors
for MU and MS, respectively, AdoCbl and MeCbl), on LPS-
induced NF-𝜅B activation in vitro, using a canonical reporter
assay. Although the various incoming forms of Cbl are all
reduced or dealkylated soon after cell entry, prior to MS/MU
cofactor formation [60], the different incoming forms affect
both the rate and ratio of formation of the two known
active cofactors, AdoCbl/MeCbl [60–62]. Theoretically, this
variability in Cbl cofactor formation may impact on the
effects of Cbls in immune challenge with respect to NF-𝜅B
activation. Thus, it was important to make this comparison.
RAW 264.7 macrophage cells, stably transfected with NF-
𝜅B luciferase reporter construct, were preincubated for 1 h
with increasing concentrations (1–10–100𝜇M) of Cbls. Upon
LPS stimulation, none of the five Cbls significantly affected
or inhibited LPS-driven NF-𝜅B activation at 1 h, with no
significant inhibitory effect on NF-𝜅B at a later time point
(24 h). CNCbl alone slightly stimulated NF-𝜅B activity, but
only at the 1 h time point andwhen tested at the concentration
of 1 𝜇M (Table 3).
In two separate experiments, each performed in triplicate,
RAW246.7 cells, stably transfected with NF-𝜅B luciferase
reporter construct, were seeded in 96-well plates and prein-
cubated for 1 h with increasing concentrations (1–10–100𝜇M)
of individual Cbls, followed by stimulation with E. coli LPS
(1 𝜇g). At 1 h, and 24 h, following LPS in the respective exper-
iments, cells were processed for measurement of luciferase
activity. Basal values of fluorescence were 2.60 ± 0.38 and
3.77 ± 0.31 for 1 h and 24 h incubation, respectively. Data
are expressed as a mean ± SEM of triplicate observations.
∗
𝑃 < 0.05 versus LPS alone.
3.2. Endogenous Cobalamins Enhance Survival in Acute Endo-
toxaemia. As there was no observable difference between the
effects of alkyl and non-alkyl Cbls on NF-𝜅B in vitro, we
chose to focus these first investigations in vivo principally
on HOCbl, as a clinically licensed Cbl form, known to be
partially converted on cell entry to the two Cbl cofactors,
MeCbl and AdoCbl, for MS and MCM, respectively [63].
Furthermore, at supraphysiological doses of 5 g i.v., HOCbl,
as a clinical cyanide antidote, has shown remarkable pro-
tection against corollary inflammation (analogous to the
inflammation seen in SIRS, sepsis, and septic shock), that
goes beyond merely acting as a magnet for CN [8].
We therefore next decided to see if the lethality
survival protection also conferred by HOCbl in a sep-
sis/endotoxaemia mouse model [7] was reproducible in a
different strain and in a more acute endotoxaemia model.
Some groups of animals were alternatively treated with
the relatively novel, intracellular Cbl, glutathionylcobalamin
(GSCbl) [61, 64] whose clinical effects are untested in sepsis,
or withN-acetyl-cysteinyl-cobalamin (NAC-Cbl), a synthetic
Table 3: Effects of the naturally occurring endogenous cobalamins
in the NF-𝜅B gene reporter assay.
Treatments NF-𝜅B reporter assay (fold increase over basal)
1 h 24 h
LPS 5.63 ± 0.37 4.60 ± 0.21
CNCbl (𝜇M)
1 ∗7.10 ± 0.30 5.70 ± 0.90
10 5.53 ± 0.29 6.60 ± 1.70
100 5.23 ± 0.62 5.53 ± 0.74
GSCbl (𝜇M)
1 6.33 ± 0.37 5.66 ± 0.67
10 6.25 ± 0.32 5.63 ± 0.63
100 5.98 ± 0.26 5.17 ± 0.84
MeCbl (𝜇M)
1 6.10 ± 0.10 6.53 ± 1.74
10 6.10 ± 0.15 5.11 ± 1.06
100 6.00 ± 0.58 5.26 ± 0.62
HOCbl (𝜇M)
1 5.67 ± 0.20 5.73 ± 0.91
10 5.98 ± 0.26 5.57 ± 0.78
100 7.00 ± 1.10 6.10 ± 0.66
AdoCbl (𝜇M)
1 6.23 ± 0.39 5.36 ± 0.77
10 6.26 ± 0.90 5.40 ± 0.70
100 6.20 ± 0.61 4.53 ± 0.32
cobalamin, used as a non-endogenously occurring, thiol Cbl
comparison. To gain some information on potential clinical
dosage, all Cbls were tested in two distinct, high dosing
regimes, with or without prophylactic pretreatment.
In a severe sepsis protocol (LPS+D-Gal), using C57BL/6
mice, we administered a relatively lowdose ofCbls (0.2mg/kg
i.p.), equivalent to a maximal concentration of approximately
1 𝜇M (considering a total blood volume of 2.5mL in the
mouse, this concentration being well within the range tested
in vitro). Individual Cbls were administered i.p. −1 h prior to
LPS+D-Gal and then given in repeated doses at +1, +2, +6,
and +22 h after LPS+D-Gal. Alternatively, a high dose Cbl
protocol (40mg/kg i.p.) was administered only twice, at +2
and +22 h after LPS+D-Gal, to assess its potential as a rescue
regimen.The urine of all Cbl-treated animals was red, within
1 h of administration, an indicator of rapid, high, systemic Cbl
saturation (data not shown).
LPS+D-Gal mice rapidly reached 88.9% mortality by 8 h.
This did not change further up to 24 h. Animals treated
with the relatively low-dose regimen of GSCbl or NAC-Cbl,
were protected in the early, 4–8 h time frame (Figure 2(a)).
During this period all Cbl-treated animals also exhibited less
huddling and pilo-erection (data not shown).
At 8 h after LPS+D-Gal, all relatively low-dose Cbl treat-
ments afforded 25% survival, +𝑃 < 0.05 versus LPS+D-
Gal alone (Figure 2(a)). However, only low-dose HOCbl
treatment maintained this level of protection up to 24 h
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Figure 2: HOCbl protects mice against experimental endotoxaemia. In (a) and (b) mice (𝑛 = 8 and 7, resp.) were treated with HOCbl or
GSCbl or NAC-Cbl following two distinct protocols, in addition to being injected with LPS (0.1mg/kg i.p.) + D-Galactosamine (1 g/kg i.p.).
Impact on lethality was followed for a total of 5 days. (a) Cobalamins were administered at a dose of 0.2mg/kg i.p. −1 h, +1 h, +2 h, +6 h,
and +22 h and compared to controls given LPS + D-Galactosamine injection alone (Time 0 h). ∗𝑃 < 0.05 for GSCbl/NAC-Cbl and + for
HOCbl when tested against LPS+D = Gal (𝑛 = 9), using the Chi-square or Kaplan-Meier tests. (b) Cobalamins were administered at a dose
of 40mg/kg i.p. +2 h and +6 h and compared to controls given LPS + D-Galactosamine injection alone (Time 0 h). ∗𝑃 < 0.01 for NAC-Cbl
and + for GSCbl/HOCbl, when tested against LPS+D-Gal (𝑛 = 9), using the Chi-square or Kaplan-Meier tests.
(Figure 2(a)). (Indeed, as regards the long-termoutcomes, 8 h
seemed to be a watershed time point at which the outcome
was determined for all groups.) Paradoxically, in view of its
early protective effects at the lower dose, the high-doseGSCbl
regimen was less protective within the first 8 h. High-dose
NAC-Cbl, which again provided some degree of protection
in the first 6 h, was not significantly different from controls
at 24 h. In contrast, high-dose GSCbl and HOCbl, despite
the lesser protection of the former in the first hours, offered
a consistent 28.60% survival up to 24 h, +𝑃 < 0.01 versus
LPS+D-Gal alone (Figure 2(b)).
Later, at 72 h following LPS+D-Gal, in the GSCbl high-
dose group, mortality was equal to that observed in the NAC-
Cbl high dose group, 85.72%, close to that of LPS+D-Gal
control animals, though this increase in mortality was a late
event: with 28.60% survival to 54 h in this group, perhaps
indicative of the general Cbl protective trend. Nonetheless,
the 25% and 28.60%, respectively, of mice that were alive at
24 h, in each of the two distinct, low- or high-dose, HOCbl-
treated groups, exhibited continued survival up to 72 h, /+𝑃 <
0.05 versus LPS+D-Gal alone/+𝑃 < 0.01 versus LPS+D-Gal
alone (Figures 2(a) and 2(b)) and beyond (data not shown).
II. Since these initial endotoxaemia studies might be
considered underpowered, we repeated the lethality survival
experiments using larger groups of mice (𝑛 = 12) and
focussing on HOCbl alone, as having previously shown
the most consistent protective effects. This time, given the
trend towards improved survival seen at the higher HOCbl
dose, two distinct ultra-high doses of HOCbl (40mg/kg and
80mg/kg) were tested, with a more concise dose/time frame,
+2 h and +4 h only for the 40mg/kg, and, in the case of the
80mg/kg dose, a single bolus administration at +2 h. The
significant survival advantage of HOCbl treatment results
demonstrated over 5 days, in Figures 3(a) and 3(b), not only
shows that our HOCbl data is consistently reproducible, but
also that increasing the dose of HOCbl significantly increases
survival, from 25% up to 33.333%: +𝑃 < 0.01 for HOCbl
(80mg/kg) by using the Kaplan-Meyer test. By comparison,
at 24 h in the LPS-only group, there was 90% mortality.
To gain information about the mechanisms behind the
consistent protection afforded by HOCbl, and to observe any
potential impact on the NOS, a non-lethal protocol was next
deployed. Then the expression of inflammatory mediator
genes in liver and lung was analysed, in both the pro- and
anti-inflammatory phases of the immune response, at the 4 h
and 24 h time points.
3.3. HOCbl Selective Promotion/Modulation of eNOS/iNOS
mRNA, Inhibition of IL-1𝛽, and Cox-2 Expression: 4 h Time
Point. The early effects of HOCbl treatment on eNOSmRNA
appeared organ dependent, with significant promotion of
eNOSmRNA in the lung and attenuation in the liver (Figures
4(a) and 4(b)). For eNOS, in LPS-only animals we observed
a decrease in the lung of −2.9 ± 0.1, whereas there was
an increase of 2.1 ± 0.1-fold change in LPS+HOCbl-treated
animals (Figure 4(a)). Paradoxically, in the liver of LPS-only
treated animals, there was an increase of eNOS expression
of up to ∼15-fold compared to up to ∼4-fold change only in
LPS+HOCbl—treated animals (Figure 4(b)).
Liver and lung iNOS and COX-2 gene expression levels
were increased in LPS-only treated animals when compared
to that of PBS-only injected mice, whose value was set
as 1. However, as for eNOS, the effects of HOCbl on
iNOS expression were once more organ selective, failing to
inhibit the rise in iNOS mRNA in the lung, but attenuating
Mediators of Inflammation 7
12
10
8
6
4
2
0
0 2 4 6 8 24 48 72 96 120
M
ic
e (
nu
m
be
r)
Time after LPS (h)
+ HOCbl (40mg/kg)
+ HOCbl (80mg/kg)
∗
∗
LPS+D-Gal
(a)
+ HOCbl (40mg/kg)
+ HOCbl (80mg/kg)
Time after LPS (h)
100
80
60
40
20
0
Su
rv
iv
al
 (%
)
0 2 4 6 8 24 48 72 96 120
∗
∗
LPS+D-Gal
(b)
Figure 3: Ultra-high dose HOCbl consistently improves survival in experimental endotoxaemia. Mice (𝑛 = 12 per group: 2 Cbl active
treatment groups plus 1 LPS-only group) were treated with HOCbl, following two distinct protocols, +40mg/kg at 2 h and +4 h post LPS +
D-Gal, and +80mg/kg at only +2 h following LPS (0.1mg/kg i.p.) + D-Galactosamine (1 g/kg i.p.). Impact on lethality was followed for a total
of 5 days. ∗𝑃 < 0.05 for HOCbl at both doses, when tested against LPS+D-Gal (𝑛 = 12), using the Chi-square test. ∗𝑃 < 0.01 for HOCbl
(80mg/kg) by using the Kaplan-Meier test.
it in the liver (Figures 4(c) and 4(d)). Strikingly, in spite
of HOCbl’s failure to completely inhibit iNOS expression,
HOCbl was a consistent inhibitor of COX-2 mRNA in both
liver and lung, bringing its degree of expression back to
and below that of PBS-injected mice (Figures 4(e) and 4(f)).
HOCbl treatment also had a consistent regulatory effect on
IL-1𝛽 expression, which was moderately and significantly
decreased in lung and completely inhibited in liver (Figures
4(g) and 4(h)).
3.4. HOCbl Has Early Promotional Effects on Translation of
eNOS/iNOS Protein. To determine efficiency of translation
of the post-LPS increased NOS mRNA, we assessed eNOS
and iNOS protein expression by Western blot in 4 h liver
samples. As predicted by our hypothesis that sepsis may
involve a failure in translation of the NOS, this revealed
that whilst in the LPS-only challenged group there was
a significant depression of eNOS protein translation, that
was at odds with its high mRNA expression, HOCbl sig-
nificantly promoted eNOS protein translation, above the
levels of both PBS control and LPS-only treatment groups
(Figure 5(a)). A similar paradoxical pattern was observed in
hepatic iNOS protein translation, with significant depression
of iNOS protein translation in the LPS-only challenged
group, and promotion of iNOS protein in the HOCbl+LPS
treated group (Figure 5(b)). We confirmed that these effects
of HOCbl on NOS protein promotion were not random
or artifactual, but were specific to Cbl, by repeating the
LPS non-lethal endotoxaemia experiment using either GSCbl
or NAC-Cbl treatment and performing Western blots for
eNOS/iNOS protein. Once again, we observed a signif-
icant early promotion of eNOS/iNOS protein by these
other Cbls, when compared to LPS only (Figures 5(a) and
5(b)).
3.5. HOCbl Moderates High ∙𝑁𝑂 Synthesis at 4 h and
24 h after LPS. However, when NOS activity was measured
(using a nitrite production assay) both in the early post-
LPS challenge, pro-inflammatory phase and in the late anti-
inflammatory, resolution phase, a further paradoxical result
emerged, suggesting that HOCbl may exert some post-
translational modification of NOS activity. Levels of nitrite
at 4 h showed an inverse relation to levels of NOS protein,
with significantly higher levels of nitrite in the LPS-only
eNOS/iNOS-depressed group and significantly lower levels of
nitrite being generated in the HOCbl/eNOS/iNOS-promoted
group (Figure 6(a)). (That this was a general, reproducible
Cbl effect was confirmed, as stated previously, by also doing
theWestern blot with 4 h GSCbl/NAC-Cbl-treated liver sam-
ples and also running the NOS activity assay with both thiol-
Cbl treated samples.) Here we again observed a correlation
between GSCbl/NAC-Cbl promoted high NOS protein in the
Western blots and decreased nitrite in the NOS activity assay
(Figure 7).
At 24 h following LPS, levels of NOS-derived nitrite, as
measured in tissue samples, were even higher than at 4 h in
both the LPS-only and HOCbl-treated groups. Nevertheless,
HOCbl consistently showed relatively less nitrite production
than LPS only, in both lung and liver tissue samples (Figures
6(b) and 6(c)).
3.6. HOCbl Regulates TNF-𝛼 Expression and Protein but
Leaves Circulating IL-6 Protein Levels Unchanged. Since high
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Figure 4: HOCbl selectively modulates NOS enzymes and inhibits COX-2, IL-1𝛽 mRNA, in lung and liver, at 4 h following LPS-induced
endotoxaemia. Mice (𝑛 = 5) were treated with HOCbl, at the low dose protocol (0.2mg/kg i.p.) and compared to LPS only (0.1mg/kg i.p.
at time 0 h). Organs (lung and liver) were harvested at 4 h after LPS and gene expression was quantified in tissue extracts by real-time PCR,
using GAPDH and RPL32 as internal standards. ((a), (b)) eNOS mRNA data; ((c), (d)) iNOS mRNA data; ((e), (f)) COX-2 mRNA data; ((g),
(h)) IL-1𝛽mRNA data. Values are a mean ± SEM of triplicate observations. ∗𝑃 < 0.05 versus vehicle (PBS-treated) control; +𝑃 < 0.05 versus
LPS-only group.
iNOS expression/protein and ∙NO activity in the sepsis liter-
ature are associated with high TNF-𝛼, IL-6, and ensuing tox-
icity, we evaluated how HOCbl might impact upon systemic
levels of TNF-𝛼 and IL-6 triggered by LPS. Plasma levels of
these cytokines were quantified using ELISA. Levels of IL-
6 protein were not significantly lower in the HOCbl-treated
group (Figure 8(a)) However, HOCbl treatment significantly
(𝑃 < 0.05) attenuated the post-LPS-induced increase in
circulating plasma TNF-𝛼, as measured at the 4 h time point,
(∼50% reduction: Figure 8(b)). Consistent with its effects on
plasma TNF-𝛼, HOCbl also showed some protection from
the inhibitory effects of LPS on TNF-𝛼 mRNA in the lung
and significant attenuation of TNF-𝛼mRNA in liver (Figures
8(c) and 8(d)).
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Figure 5: Early (4 h) promotional effect of HOCbl on iNOS and eNOS protein expression in liver samples from endotoxemic mice: mice
(𝑛 = 5) were treated with HOCbl at the low dose protocol (0.2mg/kg i.p.) at –1 h, +1 h, and +2 h and challenged with LPS (0.1mg/kg i.p.)
at time 0. Liver samples were collected and processed as described in Materials and Methods, for the Western blot analysis of iNOS and
eNOS protein expression. Upper panels ((a), (b)) showmembranes probed for iNOS, eNOS, with tubulin as the loading control; lower panels
show densitometric analysis of the blots. Values are a mean ± SEM of triplicate experiments. ∗𝑃 < 0.05 versus vehicle (PBS-treated) control;
+
𝑃 < 0.05 versus LPS group.
3.7. HOCbl Late Effects on NOS and Cox-2 mRNA: 24 h Time
Point. In the resolution phase of the immune response to
LPS, the effects of HOCbl treatment on NOS expression
displayed a degree of organ selectivity, though most notable
with respect to iNOS expression. Whilst HOCbl did not
change LPS-induced eNOS mRNA inhibition in the lung, it
significantly attenuated its inhibition in the liver, from−75- to
−58 fold-change, respectively, for LPS only and LPS+HOCbl
(Figures 9(a) and 9(b)).
HOCbl effects on iNOS mRNA in the lung were more
distinctive, with ∼80% inhibition compared to LPS-only
(vehicle group). In the liver, HOCbl treatment attenuated the
LPS-induced inhibition of iNOS mRNA by ∼40% (Figures
9(c) and 9(d)). The consistent HOCbl tissue inhibition of
Cox-2 mRNA, seen at the early pro-inflammatory phase time
point of 4 h, persisted at 24 h, showing a significantly greater
degree of inhibition than LPS-only: 7- versus 2.5-fold for LPS-
only in the lung; 115- versus 50-fold for LPS-only in liver
(Figures 9(e) and 9(f)).
3.8. HOCbl Inhibition of HMGB1mRNA at 24 h following LPS.
Given the early regulatory impact of HOCbl on NOS/ ∙NO
activity, and COX-2, IL-1𝛽, and TNF-𝛼, we expected to see
related downstream beneficial effects on expression of the
late (≥18 h) effector of endotoxaemia, high mobility group
box 1 (HMGB1). This prediction was confirmed. Where LPS-
only presented an inconsistent picture, HOCbl treatment
consistently inhibited HMGB1 mRNA: in the lung, from
an increase of 2.5 in LPS-only to a near threefold decrease
(setting levels of expression even lower than those observed
in the control group, taken as a value of 1); and in the liver,
to a more significant degree, even beyond the remarkable
inhibitory effect of LPS-only (Figures 9(g) and 9(h)).
To conclude the 24 h gene expression analyses, tissue lev-
els of IL-1𝛽 and TNF-𝛼mRNAwere also quantified using RT-
PCR. In resolution, HOCbl treatment significantly increased
inhibition of hepatic IL-1𝛽 (in line with its inhibitory effect
at 4 h) and inhibition of TNF-𝛼 in the lung, whilst also,
paradoxically, decreasing LPS inhibition of TNF-𝛼 in the liver
(Table 4). Of note was the fact that the late effects of HOCbl
on TNF-𝛼 mirrored the degree of late iNOS expression, in
both lung and liver, as, indeed, did LPS-only (Figures 9(c) and
9(d) and Table 4).
4. Discussion
Our studies present a picture of complex and far-reaching
homeostatic regulation of the activation, expression, and
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Figure 6: Modulatory effects of HOCbl on NOS activity in tissue homogenates of endotoxemic mice at 4 h and 24 h. Liver ((a), (c)) and lung
(b) tissue samples were collected 4 h and 24 h after LPS challenge (0.1mg/kg; i.p.); two groups of mice (𝑛 = 5 per group) having previously
been treated with HOCbl (resp., 0.2mg/kg i.p. at −1 h, +1 h, and +2 h and at −1 h, +1 h, +2 h, +6 h, and +22 h) and also challenged with LPS at
time 0. NOS activity at 4 h and 24 h was assayed as described in Materials and Methods, and shown as 𝜇mol of NO generated per 𝜇g protein.
Values are a mean ± SEM of triplicate observations. ∗𝑃 < 0.05 versus vehicle (PBS-treated) control; +𝑃 < 0.05 versus LPS group.
Table 4: Effects of HOCbl on pro-inflammatory cytokine gene expression, at 24 h following LPS-induced endotoxaemia.
Gene Organ LPS LPS + HOCbl 𝑃 value (versus LPS)
IL-1𝛽 Liver −8.30 ± 0.30 −10.6 ± 0.3
∗ 0.0056
Lung 2.70 ± 0.50 2.1 ± 0.1 0.3046
TNF-𝛼 Liver −86.90 ± 0.10 −68.6 ± 0.2
∗
<0.0001
Lung −2.10 ± 0.20 −11.4 ± 0.1∗ <0.0001
Mice were treated with HOCbl at the low dose protocol (0.2mg/kg i.p. at −1 h, +1 h, +2 h, +6 h, and +22 h) and compared to LPS only (0.1mg/kg i.p. at time
0 h). Twenty-four hours after LPS stimulation, organs (liver and lung) were harvested and processed for assessment of IL-1𝛽, TNF-𝛼, gene expression by real-
time PCR, using GAPDH and RPL32 as internal standards. Values are a mean ± SEM of triplicate observations. ∗denotes statistical significance for 𝑃 < 0.05.
translation of NOS, ∙NO synthesis, and inflammatory medi-
ators by HOCbl during the immune response. We propose
that this regulation accounts for the noted survivals in
rodent endotoxaemia, both in our more acute, septic shock
models I and II (a modest but significant 25%/28.60%, and
25%/33.333%, survival) and in a previous sub-acute, sepsis
model (performed with CNCbl/HOCbl—𝑛 = 10 animals per
group—30%/40% survival [7]). The regulation we show here
may also explain the observed organ/tissue-protective effects
of HOCbl in the clinical treatment of CN poisoning and
the ensuing shock, which appear to go beyond what may be
expected from the Cbl binding of CN alone [8]. Furthermore,
given the supraphysiological, saturating doses of Cbl used in
our studies, if Cbl had been acting just as an ∙NO scavenger,
or even as a NOS inhibitor, it seems unlikely that it would
have permitted the increasing rise inNOS activity (as indexed
by nitrite), both early and late, or that its effects would be so
subtle, complicated, and ultimately beneficial.
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Figure 7: The effects of thiol Cbls on activity of NOS. Liver tissue
samples were collected 4 h after LPS challenge (0.1mg/kg; i.p.); 4
groups of mice (𝑛 = 5 per group) having previously been treated
with either LPS-only or HOCbl/or GSCbl or NAC-Cbl plus LPS at
time 0 h (0.2mg/kg i.p. at −1 h, +1 h, and +2 h and at −1 h, +1 h, +2 h,
+6 h, and +22 h). NOS activity at 4 h was assayed as described in
Materials and Methods, and shown as 𝜇mol of NO generated per
𝜇g protein. Values are a mean ± SEM of triplicate observations.
∗
𝑃 < 0.05 versus vehicle (PBS-treated) control; +𝑃 < 0.05 versus
LPS group.
4.1. Paradoxes of Thiol Cobalamin Effects. The thiol Cbls, on
the other hand, present some mysteries, about which one
can only give speculative answers at this point. The survival
advantage exhibited in the early hours by comparatively
low dose GSCbl/NAC-Cbl treated animals, but not with
HOCbl treatment, may be due to the known higher reduction
potential/lability of thiol Cbls [64], resulting in more rapidly
available intracellular Cbl. Cbl is likely to be, at least in part,
functionally deficient in sepsis, as indexed by the down-
regulation of the Cbl receptors, megalin and cubilin, in
the kidneys of endotoxaemic mice [65], the kidney being
known, as a Cbl homeostatic regulator, to reduce its Cbl
uptake in states of Cbl deficiency [66]. Pertinently, megalin
is down-regulated via the LPS-induced ERK1/2 signaling
pathway [67], through which, as noted earlier, both Cbl
and ∙NO achieve their coincidentally regulatory, beneficial
effects.
Although the beneficial supply of some extra GSH, as
a consequence of thiol Cbl lability, might be proposed
as an alternative explanation for early survival protec-
tion, it is noteworthy that, at the higher dose, GSCbl
showed no early hours protection. Moreover, in a new
series of endotoxaemia lethality, in vivo survival studies
that compared protective effects of all endogenous Cbls
against those of GSCbl and NAC-Cbl, we observed that
thoughGSCbl/NAC-Cbl still consistently conferred the same
early/pre-8-hour protection compared to the 4 other Cbls,
paradoxically, both thiol Cbls repeatedly produced poor
long-term survival outcomes, equivalent to or worse than
LPS-only, whereasHOCbl/CNCbl/MeCbl/AdoCbl all consis-
tently showed significant protection, with CNCbl/MeCbl in
particular, producing even better survival results than the
current HOCbl-centred study (Brancaleone, Dalli et al. 2011,
unpublished data).
GSCbl is certainly known to produce a more rapid
early increase in MS activity (together with fourfold greater
formation of AdoCbl), when compared to HOCbl [61]. Such
an increase in MS activity, normally rapidly deactivated by
oxidative stress [68–70], would increase synthesis of the
methyl donor, S-adenosylmethionine (SAM), which inhibits
LPS-induced gene expression by modulating histone methy-
lation [71]. Whilst this may have initial short-term benefits,
as observed, there are also negative long-term consequences
from excessive inhibition of the necessary, pro-inflammatory
gene expression at this stage.This may be whyMS expression
and activity are transiently decreased by 25% and 30% early
on in the normal pro-inflammatory phase of the immune
response to LPS [72], as well as to allow for GSH synthesis
modulation [72].
The consequent, equally paradoxical failure of the other
thiol Cbl, NAC-Cbl, to significantly increase survival beyond
8 h, at both high- and low-dose protocols, may also be
attributable to the fact that NAC is particularly unstable as
a Cbl ligand and may therefore have acted independently of
Cbl as NAC alone. Further, though NAC can (1) act as an
antioxidant by increasing GSH levels (2) it can equally act
as a pro-oxidant [73], increasing disulfides, GSSG, [74] and
(3) is counter-indicated in sepsis, since, whilst NAC enhances
phagocytosis, it also suppresses the bactericidal respiratory
burst in ICU patients, with potential negative outcomes [75].
Indeed, consistent with this independent, paradoxical
observation, additional data from our in vivo endotoxaemia
model shows that in the early 4 h phase of the immune
response NAC-Cbl, in contrast to HOCbl/GSCbl, sig-
nificantly increases circulating PMN, specifically gran-
ulocytes, yet decreases the intensity of CD11b ex-pression
(see Supplementary data available online at http://dx.doi.org/
10.1155/2013/741804 (and Researchgate)).The adhesionmole-
cule/complement receptor, CD11b, is a marker of neutrophil
activation, and its high expression normally correlates with a
strong respiratory burst [76].
It is conceivable then that such NAC-promoted suppres-
sive effects ultimately outweighed the very early benefits in
survival protection conferred by NAC-Cbl.
4.2. Cbl, NF-𝜅B, and iNOS. The initial in vitro observation
that all major endogenous Cbls do not inhibit NF-𝜅B acti-
vation, even at 24 h, may appear surprising, particularly in
view of the Cbl beneficial outcomes in vivo. However, it has
previously been shown in vivo that early inhibition of NF-𝜅B
in immune challenge increases and prolongs inflammation,
and that persisting late NF-𝜅B activation (24/48 h) permits its
resolution [77].Moreover, this failure to inhibit NF-𝜅B byCbl
during inflammation, with positive outcomes, has now also
been observed by a groupwhowere aware of our findings [57]
and, independently, in aCbl cancermodel byMarguerite et al.
(2012, Marc Marten personal communication to Wheatley).
Further, since activation of NF-𝜅B is linked to induc-
tion of iNOS, and since inadequately low levels of ∙NO—
and, indeed, iNOS gene knockout in mice [78]—and NOS
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Figure 8: Selective effects of HOCbl on IL-6 and TNF-alpha at 4 h following LPS-induced endotoxaemia. Mice (𝑛 = 5) were treated with
HOCbl, at the low dose protocol (0.2mg/kg i.p.) at −1 h, +1 h, and +2 h and compared to LPS (0.1mg/kg i.p. at time 0). Organs (lung and liver)
were harvested at 4 h subsequent to LPS, and gene expression quantified in tissue extracts by real-time PCR, using GAPDH and RPL32 as
internal standards. ELISA was used to measure plasma levels of IL-6 (a) and TNF-𝛼 (b). Tissue expression of TNF-𝛼mRNA in lung (c) and
liver (d) extracts. Data are a mean ± SEM of 5 mice per group. ∗𝑃 < 0.05 versus vehicle (PBS-treated) control; +𝑃 < 0.05 versus LPS group.
inhibitors in clinical trials [79, 80] have been implicated in
sepsis morbidity and mortality [81], we adopted the hypothe-
sis thatNOS translationmay, in contradiction to the common
view, actually be depressed in sepsis and NOS catalytic
activity “uncoupled” or malfunctioning. Previously observed
high ∙NO in sepsis is believed to comprise a greater ratio of
the more toxic ∙NO species, such as peroxynitrite, ONOO-
[82], which inhibits eNOS [83], as opposed to more antiox-
idant/cytotoxic ∙NO forms, such as S-nitrosothiols/GSNO
[84, 85] or ∙NO itself; although overhigh levels of GSNO also
have negative effects in sepsis-like inflammation [85]. Since
Cbl is known to promote GSH [3, 86–88], whose synthesis
is induced simultaneously with that of iNOS [89], it should
theoretically alter the ratio of GSNO/ ∙NO to ONOO- and
related species [43], so that the more positive actions of
∙NO predominate [42] (Figure 10). Therefore, we predicted
that Cbl would not inhibit iNOS expression and translation
early on. This proved correct, with significant HOCbl (and
GSCbl/NAC-Cbl) early promotion of both iNOS and eNOS
proteins and significantly lower LPS-only iNOS/eNOS pro-
tein. Since eNOS is known to be depressed in sepsis, with
adverse cardiovascular consequences [90], this early effect of
Cbl may have positive clinical implications.
There is an apparent contradiction in the data showing
relatively low iNOS/eNOS mRNA leading to strikingly high
protein translation in the LPS+HOCbl treated animals, in
direct contrast to the LPS-only group, where strikingly
high iNOS/eNOS mRNA yielded much lower levels of
iNOS/eNOS protein.That this is not an artefact, but a specific
Cbl effect, also observed by others [47], is seen by the
comparable inverse results achieved with the two, thiol Cbls.
(These collective Cbl results were alsomirrored by decreasing
nitrite/NOS activity, in inverse proportion to the ascending
levels of HOCbl/GSCbl/NAC-Cbl iNOS protein.)
We propose that this paradox may actually be an index
of Cbl/NOS regulation in endotoxaemia and that the high
mRNA levels in LPS-only animalsmay be due to the observed
phenomenon of “relaxed control of RNA synthesis” when
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Figure 9: HOCbl modulates eNOS/iNOS, COX-2, HMGB1 gene expression in lung and liver at 24 h subsequent to LPS-induced
endotoxaemia. Mice (𝑛 = 5) were treated with HOCbl (0.2mg/kg i.p low dose regimen (Table 1)) and compared to LPS 0.1mg/kg (given
i.p. at time 0 h). Organs (lung and liver) were harvested at 24 h after LPS and gene expression was quantified in tissue extracts by real-time
PCR, using GAPDH and RPL32 as internal standards, and PBS-injected group set as 1. ((a), (b)) eNOS mRNA data; ((c), (d)) iNOS mRNA
data; ((e), (f)) COX-2 mRNA data; ((g), (h)) HMGB1 mRNA data. Values are a mean ± SEM of triplicate observations. ∗𝑃 < 0.05 versus
vehicle (PBS-treated) control; +𝑃 < 0.05 versus LPS group.
SAM/methyl groups are deficient [92], as in folate or Cbl
deficiency [93], thus consequential on the functional Cbl
deficiency of endotoxaemia/sepsis, and more permanent
MS inactivation by LPS, discussed earlier. Furthermore,
it is theoretically possible that abnormal cell function in
sepsis may result in much of the mRNA produced by
the LPS-only group being “masked” and unavailable for
efficient translation. It is possible also that the translated
protein may be unstable and degrade at a faster rate. This
is certainly known to be the case with eNOS mRNA in
hypoxia [94] and in the presence of high TNF-𝛼 [95], both
characteristic of sepsis. In contrast, given Cbl’s impact on
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Figure 10: Hypothetical scheme showing how cobalamins may modulate the NOS/ ∙NO species, both indirectly and directly, with
downstream effects, during the course of the immune response. Immune challenge upregulates—via the AP-1/Ras signalling pathway—the
circulating Cbl carrier proteins, haptocorrins, /HC-TCI & III (which, when desialylated, are taken up by the hepatic Ashwell receptor, thus
transporting more MeCbl to the liver for increased synthesis of acute phase proteins). At the same time, the Cbl tissue carrier proteins, the
transcobalamins, /TCII are also upregulated, as a result of crosstalk between the transcription factors, NF-𝜅B and Sp-1, the TCII promoter.
The increased supply of intracellular Cbl is partly converted to the active cofactors, AdoCbl andMeCbl, in a high AdoCbl to lowMeCbl ratio.
When methionine synthase/MS, along with SAM synthesis, is initially decreased by LPS challenge in activated monocytes/macrophages,
methylmalonyl CoAmutase/MU activity takes precedence [91], triggering increased expression of TCII cell receptors. Part of the consequent
extra AdoCbl synthesised may then be directed towards NOS catalysis. A combined proportional increase in activity of MU and, later, MS
ensures that all the necessary components for NOS synthesis/assembly, substrates and cofactors, are in plentiful supply. This prevents excess
generation of ROS and RNIS during NOS catalysis. These are further decreased because part of the ∙NO produced may combine with GSH,
or other thiols, to form the more beneficial, antioxidant S-nitrosothiols/S-NOS. ∙NO is then released, as needed, in targeted amounts, by
the action of GSH-dependent GSNO reductase and/or possibly by interaction with HOCbl, yielding GSCbl and ∙NO. Increasing levels
of GSNO/ ∙NO rapidly downregulate IL-1𝛽, COX-2, TNF-𝛼, HMGB1 expression, and, at the conclusion of the second, anti-inflammatory
phase of the immune response also inhibit iNOS, NF-𝜅B, and down-regulate MU, MS, and CBS. The lower right part of the scheme shows
a possible direct catalytic regulation of iNOS by AdoCbl’s lower axial ligand base, the dimethylbenzimidazole (DMBI), and the adenosyl
radical, generated after NOS enzyme-induced homolysis of the Co-C bond, which would reduce formation of RNIS/ROS, increase the ratio
of ∙NO/GSNO to ONOO- and related species, and make NOS catalysis more productive, thereby lessening the duration of iNOS activity and
ensuring the beneficial effects of ∙NO predominate (see [43]).
the two coenzymes, MS and MU, upon Cbl treatment, the
septic cell should afford a degree of metabolic normality and
thus economic efficiency in transcription/translation.
A remarkable study, over half a century ago, demon-
strated that Cbl is capable of reactivating a diversity of
key enzymes after acute oxidant stress, most of them also
negatively affected in sepsis, including glucose-6-phosphate-
dehydrogenase, lactate dehydrogenase, lysine, ornithine, and
glutamic decarboxylase [96].This last is critical for the supply
of alpha-ketoglutarate in the Krebs cycle, which is depressed
in sepsis, with consequent lower ATP production that is
associated clinically with increased mortality [97]. In turn,
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supply of alpha-ketoglutarate determines the availability of L-
arginine, glutamate, and glutamine, all of which also decrease
in sepsis, with adverse consequences, in the case of L-arginine
especially for theNOS [98]. Observed low levels of L-arginine
in sepsis [99] are associated with increased reactive nitrogen
species, including high ONOO-, and reactive oxygen species
production during NOS catalysis [98], interfering with the
normal, more beneficial ∙NO cell signalling, necessary for
the efficient resolution of the pro-inflammatory phase of the
immune response.
4.3. HOCbl Reciprocal Regulation of iNOS/NO and TNF-𝛼.
iNOS-derived ∙NO is known to have a direct regulatory cor-
relation to levels of TNF-𝛼 [100, 101]. This iNOS/ ∙NO/TNF-
𝛼 regulation seems operative here with HOCbl treatment,
not LPS-only. Since HOCbl permitted a moderate rise in
∙NO (at least, as measured by NOS nitrite end-products), in
tandem with moderate levels of TNF-𝛼 mRNA and protein,
and since Cbl status has an inverse relation to TNF-𝛼 levels
[15], it seems reasonable to conclude that such Cbl/TNF-𝛼
regulation occurs downstream of HOCbl/NOS/ ∙NO regu-
lation. Additional evidence for this in our studies may be
seen even in the resolution phase of the immune response,
where HOCbl-related levels of iNOS expression showed a
direct correlation to those of TNF-𝛼, even to the degree
of inhibition, in both lung and liver tissues (Figures 9(c)
and 9(d)/Table 3). Importantly, however, in the early pro-
inflammatory phase HOCbl iNOS/ ∙NO regulation does not
completely inhibit TNF-𝛼: 50% reduction being observed
in our experiments. This is a critical point as anti-TNF-𝛼
mAb treatment increases sepsis mortality in the clinic, since
some degree of TNF-𝛼 production and consequent early pro-
inflammatory signalling is essential for an effective immune
response [102].
4.4. HOCbl Regulation of IL-6, IL-1𝛽, and Cox-2. Also note-
worthy, and crucially consistent with such HOCbl/iNOS/
TNF-𝛼 regulation, is HOCbl’s apparently selective failure to
inhibit IL-6 early on. IL-6 is essential for induction of acute
phase proteins, whilst simultaneously also decreasing pro-
inflammatory cytokines and increasing anti-inflammatory
factors [103]. IL-6 regulation of pro-inflammatory factors
includes regulation of TNF-𝛼 and IL-1𝛽 [104], expression of
the latter also determining that of Cox-2, involved in arachi-
donic acid-derived prostaglandin and leukotriene synthesis
[105]. IL-1𝛽 is rapidly expressed (∼15min post LPS) [106],
whereas iNOS, which may be induced by IL-1𝛽, is not fully
expressed until 6 h after LPS [107].
We have observed that treatment with high doses of
endogenous Cbls (HOCbl/GSCbl) promotes iNOS mRNA
expression as early as 2 h following LPS (unpublished data),
possibly fast forwarding the immune response.This, together
with the HOCbl-promoted high NOS protein, controlled
rise in ∙NO synthesis, and thence a moderate produc-
tion of TNF-𝛼/IL-6 may form a feedback loop account-
ing for the tight HOCbl regulation of IL-1𝛽, and conse-
quently also Cox-2, as seen at 4 h after LPS (Figure 10
scheme).
4.5. HOCbl Inhibition of Late HMGB1 Gene Expression.
Cobalamin-promoted NOS/ ∙NO early regulation of TNF-
𝛼/IL-6/IL-1𝛽/Cox-2 seems also to be consistent with, and
accounts for, the later inhibition of HMGB1 mRNA. If
expressed at >18 h and then released extracellularly, HMGB1
can trigger further late release of TNF-𝛼, IL-1𝛽, and inflam-
matory products from COX-2, iNOS, and excessive ROS and
RNI species, leading to pathology [108]. It is known that the
nervous system can modulate circulating TNF-𝛼 levels via
release of acetylcholine by the vagus nerve [109]. But our
studies show that Cbl—essential for acetylcholine synthesis
[110]—is the first known endogenous inhibitor of lateHMGB1
mRNA expression. Both nicotine and ethyl-pyruvate have
been used to block extracellular release of HMGB1 [109] but,
in addition to the fact that HOCbl appears to impact on
HMGB1 much further upstream, at least in tissues, neither
drug is endowed with the safety profile of Cbl [111] and,
more pertinently, neither is known to exert such a central,
endogenous regulation of the immune response. Further
Cbl/sepsis studies should include measurement of plasma
HMGB1 levels. But, on the evidence of the general anti-
inflammatory regulation observed in our studies, we predict
that extracellular release of HMGB1, from macrophages and
PMN, should be negligible with HOCbl treatment.
4.6. ANewParadigm for theCbl/NOS/ ∙𝑁𝑂Relationship? The
theory that Cbl may impact on the NOS indirectly, through
the contribution of its two known mammalian coenzymatic
functions to NOS substrate and cofactor assembly and,
indeed, to assembly of the NOS protein itself [39], may fur-
ther explain our findings, including the Cbl-promoted high
NOS protein (Figure 10 scheme). Furthermore, a deficiency
of any of the NOS substrates and cofactors (the likely result
of Cbl functional deficiency in endotoxaemia) is known to
result in less tightly “coupled” NOS activity and increased
free radical generation [112, 113], with a corollary increase
in inflammatory mediators and prolonged period of NOS
activity, indexed by our observed higher LPS-only NOS
nitrite levels.
(In a forthcoming study we will also analyse more exactly
how Cbl may shift the ratio of ∙NO/GSNO/ONOO and
related species).
It may also be that Cbl, as AdoCbl and its radical, takes
a direct, active part in NOS catalysis, as a third mammalian
Cbl cofactor [43]. From this perspective, the high NOS
protein seen with high Cbl administration may be a classical
instance of the cofactor promoting coenzyme assembly. Such
a central, direct Cbl/NOS, catalytic interaction would further
reduce excess production of toxic forms of ∙NO, as well
as superoxide and other related ROS and RNI species.
The consequent, more precise, pro- and anti-inflammatory
signalling should again result in a shorter, more effective
period of NOS activity, thus lower detectable nitrite levels
(as seen) with the beneficial signalling and antioxidant effects
of ∙NO predominant. However, direct Cbl scavenger interac-
tions, in discrete intracellular compartments, with primarily
toxic RNIS, such as ONOO-/ONOOH/NO
2
, with which Cbl
interacts ex vivo, [114], may also play a part and cannot be
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ruled out as contributing to a more complex picture behind
our observed results (Figure 10).
5. Conclusions
These novel observations on the mechanism behind cobal-
amin protection in endotoxaemia suggest that we may be
looking at the ideal natural, selective and collective regulator
of the NOS, and thence of cytokines and other pivotal
factors, in immune challenge and sepsis. In fact, it is now
accepted that anti-inflammatory therapies (based on block-
ing a specific mediator) fail toutcourt in sepsis and that
a more modulatory approach, which regulates the homeo-
static inflammatory response, (in itself beneficial), could be
successful. Thus, our findings may have significant clinical
implications, not only for the treatment of sepsis, but also
for other analogous inflammation-driven conditions, such
as cancer and malaria, where NOS/ ∙NO deregulation, and
consequent loss of control over key inflammatory mediators,
are equally pathogenic [115, 116].
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